

CT-determined resectability of borderline resectable an adenocarcinoma following FOLFIRINOX therapy

European Radiology

31, 813-823

DOI: [10.1007/s00330-020-07188-8](https://doi.org/10.1007/s00330-020-07188-8)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Radiomics-Assisted Presurgical Prediction for Surgical Portal Vein-Superior Mesenteric Vein Invasion in Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 523543.	1.3	8
2	CT in the prediction of margin-negative resection in pancreatic cancer following neoadjuvant treatment: a systematic review and meta-analysis. <i>European Radiology</i> , 2021, 31, 3383-3393.	2.3	16
3	Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma. <i>World Journal of Gastroenterology</i> , 2021, 27, 3037-3049.	1.4	11
4	Optimized scan delay for late hepatic arterial or pancreatic parenchymal phase in dynamic contrast-enhanced computed tomography with bolus-tracking method. <i>British Journal of Radiology</i> , 2021, 94, 20210315.	1.0	3
5	How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers. <i>European Radiology</i> , 2022, 32, 56-66.	2.3	11
6	CT-diagnosed extra-pancreatic extension of pancreatic ductal adenocarcinoma is a more reliable prognostic factor for survival than pathology-diagnosed extension. <i>European Radiology</i> , 2022, 32, 22-33.	2.3	9
7	CT Radiomic Features of Superior Mesenteric Artery Involvement in Pancreatic Ductal Adenocarcinoma: A Pilot Study. <i>Radiology</i> , 2021, 301, 610-622.	3.6	36
8	Neoadjuvant therapy & vs&. upfront surgery for resectable pancreatic cancer: An update on a systematic review and meta-analysis. <i>BioScience Trends</i> , 2021, 15, 365-373.	1.1	7
9	Imaging Assessment of Pancreatic Cancer Resectability After Neoadjuvant Therapy: <i>AJR</i> Expert Panel Narrative Review. <i>American Journal of Roentgenology</i> , 2022, 218, 570-581.	1.0	11
10	Identifying optimal candidates for tumor resection among borderline and locally advanced pancreatic cancer: A population-based predictive model. <i>Pancreatology</i> , 2022, 22, 286-293.	0.5	3
11	Application of Magnetic Resonance Imaging in Neoadjuvant Treatment of Pancreatic Ductal Adenocarcinoma. <i>Journal of Magnetic Resonance Imaging</i> , 2022, , .	1.9	3
13	Computed tomography-based radiomic to predict resectability in locally advanced pancreatic cancer treated with chemotherapy and radiotherapy. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 703-715.	0.8	4
14	Retrospective Evaluation of Treatment Response in Patients with Nonmetastatic Pancreatic Cancer Using CT and CA 19-9. <i>Radiology</i> , 2022, 303, 548-556.	3.6	10
16	Prediction of Margin-€Negative Resection of Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Therapy: Diagnostic Performance of NCCN Criteria for Resection vs. CT-€Determined Resectability. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 0, , .	1.4	1
17	Current Concepts and Future Directions in Pancreatic Adenocarcinoma Staging. <i>Advances in Clinical Radiology</i> , 2022, 4, 47-58.	0.1	0
18	Predictive value of computed tomography on surgical resectability in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: Results from a prospective, multicentre phase 2 trial (NEOLAP-AIO-PAK-0113). <i>European Journal of Radiology</i> , 2023, 163, 110834.	1.2	1
19	Multidisciplinary team diagnosis and treatment of pancreatic cancer: Current landscape and future prospects. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
20	Utilization of a novel 3D radiologic scoring method to define therapeutic response and surgical candidacy. , 0, 2, .		0

#	ARTICLE	IF	CITATIONS
21	High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study. <i>European Radiology</i> , 0, , .	2.3	0